-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Up to now, a total of more than 100 listed medical device companies in A-shares have disclosed their performance reports for the first three quarters of 2021
.
In the process of rapid development of the medical device industry, which companies have outstanding performance, and which companies appear to be "powerless"? Judging from the operating income of more than 100 companies in the first three quarters of this year, industry giants performed even more brilliantly.
Among them, Mindray Medical and Intech Healthcare both achieved substantial gains, with revenues exceeding 10 billion yuan
.
According to statistics, there are a total of 12 companies whose revenue in the first three quarters of this year exceeded 5 billion yuan
.
Specifically, Mindray Medical's revenue and net profit in the first three quarters of 2021 achieved rapid growth compared with the same period in 2020, achieving operating income of 19.
392 billion yuan, a year-on-year increase of 20.
72%; achieving net profit attributable to the parent of 6.
663 billion yuan, a year-on-year increase of 24.
23%
.
As a medical device giant, Mindray Medical is cultivating the domestic market while its overseas business is also developing rapidly.
It is reported that in the domestic market, the company’s products cover nearly 110,000 medical institutions and more than 99% of the top three hospitals, monitors, ventilators, The sales of infusion pumps and other products are eye-catching; in the international market, the company has successively introduced its products in large hospitals in North America and Western Europe through years of accumulation, laying a solid global customer base and brand influence
.
Ingram Medical’s performance has also increased significantly.
In the first three quarters of 2021, revenue was 13.
647 billion yuan, a year-on-year increase of 52.
56%; net profit was 6.
943 billion yuan, a year-on-year increase of 58.
77%
.
Regarding the revenue growth, Intech Medical said it was mainly due to the increase in product sales and the increase in selling prices
.
The company is a supplier of personal protective equipment, focusing on the production and development of disposable gloves.
The main products are personal protective products, rehabilitation care products, and other products
.
In addition, 10 medical device companies including Dean Diagnostics, Oriental Bio, Yuyue Medical, Golden Mile Medical, Xinhua Medical, Blue Sail Medical, Robust Medical, Daan Gene, BGI Gene and other companies in the first three quarters of 2021 also have revenues in the first three quarters of 2021.
Both exceeded 5 billion yuan
.
Among them, the two in vitro testing companies, Hotview Bio and Oriental Bio, not only achieved high revenue growth in the first nine months of this year, but also their net profit increased by more than 100% year-on-year.
.
The third quarterly report of Rejing Biology showed that the company's net profit attributable to the parent in the first three quarters increased by 660.
26% year-on-year to 23.
7204 million yuan
.
However, compared with the net profit that surged by 74261.
79% in the first half of the year, the profit of the first three quarters of Hotview Biotech has dropped sharply.
In response, the company said in response to investors in November that it is mainly related to the situation of domestic and foreign epidemic prevention and control and testing products.
Decrease in orders is related
.
In addition, Oriental Bio's net profit attributable to the parent in the first three quarters increased by 489.
85% year-on-year to 3.
919 billion yuan.
The company said that the growth in the first three quarters was mainly due to the significant year-on-year increase in sales of related testing reagents from the beginning of the year to the end of the reporting period
.
Some medical device companies, such as Lepu Medical, Zhende Medical, Prudent Medical, and Sino Medical, appear to be "powerless" in terms of net profit in the first three quarters of this year
.
Among them, Sino Medical had a net loss of 111 million yuan in the first three quarters.
The third quarter net profit of Stable Medical and Lepu Medical dropped by 64.
95% and 2.
63% year-on-year, respectively
.
From an analysis point of view, the decline in net profit of some companies is related to the impact of centralized procurement of consumables.
For example, Lepu Medical was affected by the national centralized procurement of coronary stents in the first three quarters.
In order to reverse the situation, Lepu Medical also actively launched innovative products
.
Since the beginning of this year, Lepu Medical’s interventional non-implantable innovative product portfolio has achieved significant growth.
The revenue in the first three quarters was 610 million yuan, an increase of 1073.
24% over the same period last year
.
.
In the process of rapid development of the medical device industry, which companies have outstanding performance, and which companies appear to be "powerless"? Judging from the operating income of more than 100 companies in the first three quarters of this year, industry giants performed even more brilliantly.
Among them, Mindray Medical and Intech Healthcare both achieved substantial gains, with revenues exceeding 10 billion yuan
.
According to statistics, there are a total of 12 companies whose revenue in the first three quarters of this year exceeded 5 billion yuan
.
Specifically, Mindray Medical's revenue and net profit in the first three quarters of 2021 achieved rapid growth compared with the same period in 2020, achieving operating income of 19.
392 billion yuan, a year-on-year increase of 20.
72%; achieving net profit attributable to the parent of 6.
663 billion yuan, a year-on-year increase of 24.
23%
.
As a medical device giant, Mindray Medical is cultivating the domestic market while its overseas business is also developing rapidly.
It is reported that in the domestic market, the company’s products cover nearly 110,000 medical institutions and more than 99% of the top three hospitals, monitors, ventilators, The sales of infusion pumps and other products are eye-catching; in the international market, the company has successively introduced its products in large hospitals in North America and Western Europe through years of accumulation, laying a solid global customer base and brand influence
.
Ingram Medical’s performance has also increased significantly.
In the first three quarters of 2021, revenue was 13.
647 billion yuan, a year-on-year increase of 52.
56%; net profit was 6.
943 billion yuan, a year-on-year increase of 58.
77%
.
Regarding the revenue growth, Intech Medical said it was mainly due to the increase in product sales and the increase in selling prices
.
The company is a supplier of personal protective equipment, focusing on the production and development of disposable gloves.
The main products are personal protective products, rehabilitation care products, and other products
.
In addition, 10 medical device companies including Dean Diagnostics, Oriental Bio, Yuyue Medical, Golden Mile Medical, Xinhua Medical, Blue Sail Medical, Robust Medical, Daan Gene, BGI Gene and other companies in the first three quarters of 2021 also have revenues in the first three quarters of 2021.
Both exceeded 5 billion yuan
.
Among them, the two in vitro testing companies, Hotview Bio and Oriental Bio, not only achieved high revenue growth in the first nine months of this year, but also their net profit increased by more than 100% year-on-year.
.
The third quarterly report of Rejing Biology showed that the company's net profit attributable to the parent in the first three quarters increased by 660.
26% year-on-year to 23.
7204 million yuan
.
However, compared with the net profit that surged by 74261.
79% in the first half of the year, the profit of the first three quarters of Hotview Biotech has dropped sharply.
In response, the company said in response to investors in November that it is mainly related to the situation of domestic and foreign epidemic prevention and control and testing products.
Decrease in orders is related
.
In addition, Oriental Bio's net profit attributable to the parent in the first three quarters increased by 489.
85% year-on-year to 3.
919 billion yuan.
The company said that the growth in the first three quarters was mainly due to the significant year-on-year increase in sales of related testing reagents from the beginning of the year to the end of the reporting period
.
Some medical device companies, such as Lepu Medical, Zhende Medical, Prudent Medical, and Sino Medical, appear to be "powerless" in terms of net profit in the first three quarters of this year
.
Among them, Sino Medical had a net loss of 111 million yuan in the first three quarters.
The third quarter net profit of Stable Medical and Lepu Medical dropped by 64.
95% and 2.
63% year-on-year, respectively
.
From an analysis point of view, the decline in net profit of some companies is related to the impact of centralized procurement of consumables.
For example, Lepu Medical was affected by the national centralized procurement of coronary stents in the first three quarters.
In order to reverse the situation, Lepu Medical also actively launched innovative products
.
Since the beginning of this year, Lepu Medical’s interventional non-implantable innovative product portfolio has achieved significant growth.
The revenue in the first three quarters was 610 million yuan, an increase of 1073.
24% over the same period last year
.
